Key Takeaways AstraZeneca reported positive phase III Bax24 data in patients with resistant hypertension.Baxdrostat achieved a significant drop in 24-hour average systolic blood pressure versus placebo.Baxdrostat was well tolerated, and AstraZeneca plans to share results with global regulators.AstraZeneca (AZN) announced positive top-line data from the phase III Bax24 study evaluating the safety, tolerability and efficacy of its investigational candidate, baxdrostat, in patients with resistant hypertension. ...

宏观经济与政策 - 中国央行连续第11个月增持黄金储备，9月末黄金储备环比增加4万盎司（约1.24吨）至7406万盎司（约2303.523吨）[9] - 中国9月末外汇储备规模为33387亿美元，较8月末上升165亿美元，升幅0.5%，创2015年12月以来最高[9] - 世界贸易组织（WTO）将2025年全球货物贸易增长预测上调至2.4%，显著高于8月时的0.9%[12] 金融市场表现 - 美股三大指数集体收跌，道指跌0.2%，纳指跌0.67%，标普500指数跌0.38%[5] - 纳斯达克中国金龙指数收跌2.24%，热门中概股普跌，世纪互联跌超6%，万国数据跌超5%，百度跌超4%[5] - 现货黄金涨0.59%至3984.14美元/盎司，盘中一度触及3990美元/盎司，COMEX黄金期货收涨0.79%至4007.9美元/盎司，年内已涨超50%[6][10] - WTI原油期货收涨0.06%至61.73美元/桶，布伦特原油期货收跌0.03%至65.45美元/桶[7] 科技与新能源汽车行业 - 特斯拉推出新版Model Y，起售价为3.999万美元，较此前便宜约11%，同时公布最便宜车型Model 3标准版起售价3.699万美元[15] - 腾讯混元视觉模型Hunyuan-Vision-1.5-Thinking在国际大模型竞技场LMArena最新榜单中取得全球第3、国内第1的成绩[16] - 马斯克宣布其xAI游戏工作室将于2026年底前发布一款“大型”AI生成游戏[22] 医药行业 - 阿斯利康在研高血压药物baxdrostat在针对难治性高血压患者的后期临床试验中达到主要目标，显著降低血压[23] 其他行业动态 - 中国科学院金属研究所科研团队在固态锂电池领域取得突破，为解决界面阻抗大、离子传输效率低的关键难题提供了新路径[10] - 2025年国庆档电影总票房（含预售）破17亿元，前三名为《志愿军：浴血和平》《731》《刺杀小说家2》[11]

Dow Index Breaks Winning Streak As AMD Soars On OpenAI Deal 10/06/2025The Dow Jones Industrial Average falls in Monday's stock market while the S&P 500 and the Nasdaq score record closes. 10/06/2025The Dow Jones Industrial Average falls in Monday's stock market... The IPO sector, despite concerns that the federal government shutdown might negatively impact the debut of new companies, remains fertile ground for intrepid growth investors. Natural gas producer BKV (BKV) and cybersecurity expert SailPoint (SAIL ...

Key Takeaways Thermo Fisher partners with AstraZeneca at BioVentureHub to drive collaborative R&D in life sciences.Thermo Fisher's new Gothenburg lab at BioVentureHub will support global pharma and biotech R&D by 2026.The AZN partnership advances drug and analytical development, reinforcing Thermo Fisher's mission globally.Thermo Fisher Scientific’s (TMO) clinical research business, PPD, announced a new research and development (R&D) partnership with AstraZeneca’s (AZN) BioVentureHub in Gothenburg, Sweden. ...

阿斯利康预计该药物的年销售额最高将超过50亿美元。 10月7日，阿斯利康表示，在研高血压药物baxdrostat在一项针对难治性高血压患者的后期临床试验中达 到主要目标，显著降低血压。阿斯利康计划将在年底前递交baxdrostat的审批，并预计该药物的年销售 额最高将超过50亿美元。该药物正在临床研究中的其他适应证还包括慢性肾病和预防心力衰竭。 ...

Authored by Evgenia Filimianova via The Epoch Times,The U.S. tariff policy and its unmatched pharmaceutical market are pulling European drugmakers to invest more heavily, from new manufacturing plants to U.S. stock listings and discount pricing deals.Since early 2025, European drugmakers have stepped up their U.S. presence. In the most recent move, the United Kingdom’s giant AstraZeneca announced on Sept. 29 a direct listing on the New York Stock Exchange, just months after pledging $50 billion of U.S. inve ...

AstraZeneca said on Tuesday its drug Baxdrostat met the main goal in a late-stage study in patients with treatment-resistant high blood pressure, or hypertension. ...

合作协议核心条款 - 美国生物技术公司Algen授予阿斯利康使用其AI驱动基因编辑平台开发疗法的许可，交易价值高达5.55亿美元[1] - 阿斯利康将获得开发和销售针对免疫系统相关紊乱的获批疗法的独家权利，并向Algen支付预付款和里程碑款项[1] - 此次交易不包括阿斯利康收购Algen公司股权[3] 阿斯利康的战略与财务背景 - 阿斯利康通过收购和合作推进其细胞和基因疗法能力，目标是到2030年实现800亿美元销售额[2] - 公司呼吸和免疫学产品组合在2025年上半年产生42.3亿美元销售额，约占总收入的15%[2] - 阿斯利康在3月同意以高达10亿美元收购比利时生物技术公司EsoBiotec，以获得体内直接修饰免疫细胞的技术[3] Algen公司的技术与资源 - Algen公司首席执行官表示，其AI平台AlgenBrain能够将基因与疾病结果进行映射，帮助公司决定靶向疗法的开发重点[5] - 公司此前已融资1100万美元，投资者包括Viking Global和Illumina，目前资金充足[4] - Algen是从加州大学伯克利分校实验室分拆出来的，该实验室的生物化学家Jennifer Doudna曾因开创CRISPR技术获得诺贝尔奖[5] 合作展望与行业趋势 - 合作旨在结合阿斯利康在转化科学和临床开发方面的深厚专业知识，以加速新疗法的开发[4] - 全球制药公司越来越多地转向利用人工智能进行药物开发[2]

Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a dea... ...

AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. ...